Unlike SLFN5, no significant correlation is observed between SLFN11 expression and overall survival, but a longer radiologic progression-free survival (rPFS) is seen in CRPC patients with adenocarcinoma histology with SLFN11 overexpression vs. low SLFN11 expression in patients that are treated with platinum-based chemotherapy, and no similar effect on rPFS is observed in neuroendocrine prostate cancer [69]. The gene discussed is SLFN11; the disease is adenocarcinoma.